Journal article icon

Journal article

The Generation of an Engineered Interleukin-10 Protein With Improved Stability and Biological Function

Abstract:
Interleukin-10 (IL-10) is an immunoregulatory cytokine that plays a pivotal role in modulating inflammation. IL-10 has inhibitory effects on proinflammatory cytokine production and function in vitro and in vivo; as such, IL-10 is viewed as a potential treatment for various inflammatory diseases. However, a significant drawback of using IL-10 in clinical application is the fact that the biologically active form of IL-10 is an unstable homodimer, which has a short half-life and is easily degraded in vivo. Consequently, IL-10 therapy using recombinant native IL-10 has had only limited success in the treatment of human disease. To improve the therapeutic potential of IL-10, we have generated a novel form of IL-10, which consists of two IL-10 monomer subunits linked in a head to tail fashion by a flexible linker. We show that the linker length per se did not affect the expression and biological activity of the stable IL-10 molecule, which was more active than natural IL-10, both in vitro and in vivo. We confirmed that the new form of IL-10 had a much-improved temperature- and pH-dependent biological stability compared to natural IL-10. The IL-10 dimer protein binds to the IL-10 receptor similarly to the natural IL-10 protein, as shown by antibody blocking and through the genetic modifications of one monomer in the IL-10 dimer specifically at the IL-10 receptor binding site. Finally, we showed that stable IL-10 is more effective at suppressing LPS-induced-inflammation in vivo compared to the natural IL-10. In conclusion, we have developed a new stable dimer version of the IL-10 protein with improved stability and efficacy to suppress inflammation. We propose that this novel stable IL-10 dimer could serve as the basis for the development of targeted anti-inflammatory drugs.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.3389/fimmu.2020.01794

Authors

More by this author
Role:
Author
ORCID:
0000-0003-4677-9614
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-3911-3374
More by this author
Role:
Author
ORCID:
0000-0003-4659-8960


Publisher:
Frontiers Media
Journal:
Frontiers in Immunology More from this journal
Volume:
11
Pages:
1794-1794
Publication date:
2020-08-11
DOI:
EISSN:
1664-3224
ISSN:
1664-3224


Language:
English
Keywords:
Pubs id:
2377298
Local pid:
pubs:2377298
Source identifiers:
W3044114013
Deposit date:
2026-02-19
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP